Specific inhibitors towards Histone Deacetylases (HDACs) and Mammalian Target of Rapamycin Complex 1 (mTORC1) have been developed and demonstrate potential as treatments for patients with advanced and/or metastatic and castrate resistant prostate cancer (PCa). Further, deregulation of HDAC expression and mTORC1 activity are documented in PCa and provide rational targets to create new therapeutic strategies to treat PCa. Here we report the use of the c-Myc adenocarcinoma cell line from the c-Myc transgenic mouse with prostate cancer to evaluate the in vitro and in vivo anti-tumor activity of the combination of the HDAC inhibitor panobinostat with the mTORC1 inhibitor everolimus. Panobinostat/everolimus combination treatment resulted in significantly greater antitumor activity in mice bearing androgen sensitive Myc-CaP and castrate resistant Myc-CaP tumors compared to single treatments. We identified that panobinostat/everolimus combination resulted in enhanced anti-tumor activity mediated by decreased tumor growth concurrent with augmentation of p21 and p27 expression and the attenuation of angiogenesis and tumor proliferation via androgen receptor, c-Myc and HIF-1α signaling. Also, we observed altered expression of microRNAs associated with these three transcription factors. Overall, our results demonstrate that low dose concurrent panobinostat/everolimus combination therapy is well tolerated and results in greater anti-tumor activity compared to single treatments in tumor bearing immuno-competent mice. Finally, our results suggest that response of selected miRs could be utilized to monitor panobinostat/everolimus in vivo activity.
References
[1]
Kumar-Sinha C, Tomlins SA, Chinnaiyan AM (2008) Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8: 497–511.
Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, et al. (2008) Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 21: 1156–1167.
Litvinov IV, De Marzo AM, Isaacs JT (2003) Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 88: 2972–2982.
[6]
Abbas A, Gupta S (2008) The role of histone deacetylases in prostate cancer. Epigenetics 3: 300–309.
[7]
Coppola V, De Maria R, Bonci D (2010) MicroRNAs and prostate cancer. Endocr Relat Cancer 17: F1–17.
[8]
Sabatini DM (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6: 729–734.
[9]
Schmelzle T, Hall MN (2000) TOR, a central controller of cell growth. Cell 103: 253–262.
[10]
Guertin DA, Sabatini DM (2009) The pharmacology of mTOR inhibition. Sci Signal 2: pe24.
[11]
Sawyers CL (2003) Will mTOR inhibitors make it as cancer drugs? Cancer Cell 4: 343–348.
[12]
Ellis L, Pili R (2010) Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies. Pharmaceuticals (Basel) 3: 2411–2469.
[13]
Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA, et al. (2006) Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res 66: 8814–8821.
[14]
Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, et al. (2009) Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 69: 958–966.
[15]
Garcia JA, Danielpour D (2008) Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 7: 1347–1354.
[16]
Watson PA, Ellwood-Yen K, King JC, Wongvipat J, Lebeau MM, et al. (2005) Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res 65: 11565–11571.
[17]
Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, et al. (2003) Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4: 223–238.
[18]
Balakumaran BS, Porrello A, Hsu DS, Glover W, Foye A, et al. (2009) MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. Cancer Res 69: 7803–7810.
[19]
Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, et al. (2008) Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res 14: 3589–3597.
[20]
Kaarbo M, Mikkelsen OL, Malerod L, Qu S, Lobert VH, et al. (2010) PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells. Cell Oncol 32: 11–27.
[21]
Kulshreshtha R, Ferracin M, Negrini M, Calin GA, Davuluri RV, et al. (2007) Regulation of microRNA expression: the hypoxic component. Cell Cycle 6: 1426–1431.
[22]
O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT (2005) c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435: 839–843.
[23]
Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769–784.
[24]
Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, et al. (2008) Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 14: 4500–4510.
[25]
Ellis L, Bots M, Lindemann RK, Bolden JE, Newbold A, et al. (2009) The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood 114: 380–393.
[26]
Atadja P, Gao L, Kwon P, Trogani N, Walker H, et al. (2004) Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res 64: 689–695.
[27]
Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, et al. (2006) Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 12: 634–642.
[28]
Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, et al. (2004) The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 64: 6626–6634.
[29]
Hwang JJ, Kim YS, Kim MJ, Kim DE, Jeong IG, et al. (2010) Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells. J Urol 184: 2557–2564.
[30]
Evren S, Dermen A, Lockwood G, Fleshner N, Sweet J (2010) Immunohistochemical examination of the mTORC1 pathway in high grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinomas (PCa): a tissue microarray study (TMA). Prostate 70: 1429–1436.
[31]
Rai JS, Henley MJ, Ratan HL (2010) Mammalian target of rapamycin: a new target in prostate cancer. Urol Oncol 28: 134–138.
[32]
Wedel S, Hudak L, Seibel JM, Juengel E, Tsaur I, et al. (2011) Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001. Life Sci 88: 418–424.
[33]
Kramer OH, Knauer SK, Zimmermann D, Stauber RH, Heinzel T (2008) Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. Oncogene 27: 732–740.
[34]
Nguyen DM, Schrump WD, Chen GA, Tsai W, Nguyen P, et al. (2004) Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res 10: 1813–1825.
[35]
Martelli AM, Evangelisti C, Chappell W, Abrams SL, Basecke J, et al. (2011) Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 25: 1064–1079.
[36]
Wang LG, Liu XM, Fang Y, Dai W, Chiao FB, et al. (2008) De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol 33: 375–380.
[37]
Mahalingam D, Medina EC, Esquivel JA 2nd, Espitia CM, Smith S, et al. (2010) Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res 16: 141–153.
[38]
Ryan BM, O'Donovan N, Duffy MJ (2009) Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 35: 553–562.
[39]
Chiong E, Lee IL, Dadbin A, Sabichi AL, Harris L, et al. (2011) Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin Cancer Res 17: 2863–2873.
[40]
De Benedetti A, Graff JR (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene 23: 3189–3199.
[41]
Atadja P (2009) Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 280: 233–241.
[42]
Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, et al. (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2: 151–163.
[43]
Baudino TA, McKay C, Pendeville-Samain H, Nilsson JA, Maclean KH, et al. (2002) c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev 16: 2530–2543.
[44]
Iacopino F, Urbano R, Graziani G, Muzi A, Navarra P, et al. (2008) Valproic acid activity in androgen-sensitive and -insensitive human prostate cancer cells. Int J Oncol 32: 1293–1303.
[45]
Wu Y, Chhipa RR, Cheng J, Zhang H, Mohler JL, et al. (2010) Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival. Anticancer Res 30: 3895–3901.
[46]
Schayowitz A, Sabnis G, Goloubeva O, Njar VC, Brodie AM (2010) Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR. Br J Cancer 103: 1001–1007.
[47]
Kim JW, Mori S, Nevins JR (2010) Myc-induced microRNAs integrate Myc-mediated cell proliferation and cell fate. Cancer Res 70: 4820–4828.
[48]
Kulshreshtha R, Davuluri RV, Calin GA, Ivan M (2008) A microRNA component of the hypoxic response. Cell Death Differ 15: 667–671.
[49]
Shi XB, Tepper CG, White RW (2008) MicroRNAs and prostate cancer. J Cell Mol Med 12: 1456–1465.
[50]
Tessel MA, Krett NL, Rosen ST (2010) Steroid receptor and microRNA regulation in cancer. Curr Opin Oncol 22: 592–597.
[51]
Pesta M, Klecka J, Kulda V, Topolcan O, Hora M, et al. (2010) Importance of miR-20a expression in prostate cancer tissue. Anticancer Res 30: 3579–3583.
[52]
Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, et al. (2009) miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 69: 7165–7169.
[53]
Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, et al. (2011) Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 71: 326–331.
[54]
Hao Y, Zhao Y, Zhao X, He C, Pang X, et al. (2011) Improvement of Prostate Cancer Detection by Integrating the PSA Test With miRNA Expression Profiling. Cancer Invest.
[55]
Gurel B, Iwata T, Koh CM, Yegnasubramanian S, Nelson WG, et al. (2008) Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets. Adv Anat Pathol 15: 319–331.
[56]
Jans J, van Dijk JH, van Schelven S, van der Groep P, Willems SH, et al. (2010) Expression and localization of hypoxia proteins in prostate cancer: prognostic implications after radical prostatectomy. Urology 75: 786–792.
[57]
Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, et al. (2009) Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 115: 5541–5549.
[58]
Emmenegger U, Sridhar SS, Booth CM, Kerbel R, Berry SR, et al. (2010) A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology 28:
[59]
Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Pili R (2011) Development of a castrate resistant transplant tumor model of prostate cancer. Prostate.
